Skip to main content
. Author manuscript; available in PMC: 2017 Jan 12.
Published in final edited form as: J Nucl Med. 2016 Feb;57(Suppl 1):34S–39S. doi: 10.2967/jnumed.115.157875

TABLE 1.

Summary of Studies of 18F-FDG PET for Early Prediction of Treatment Response

18F-FDG PET metabolic response
Reference Year No. of patients included in 18F-FDG PET analysis Pathologic response criteria* Percentage of responders After indicated treatment cycle Decrease in SUV Percentage sensitivity Percentage specificity Percentage negative predictive value
Schelling et al. (8) 2000 22 pCR + pMRD 29 First, second > 45% after first or second 100 (first), 83 (second) 85 (first), 94 (second) N/A
Smith et al. (9) 2000 30 pCR-macro 38 First >20% 90 74 N/A
Rousseau et al. (10) 2006 64 >50% therapeutic effect 56 First, second > 40% after first or second 61 (first), 89 (second) 96 (first), 95 (second) 68 (first), 85 (second)
Schwarz-Dose (11) 2009 104 pCR + pMRD 16 First, second > 45% after first, >55% after second 73 63 90
Humbert et al. (32) 2012 37 pCR 38 First >75% 64 83 79
Groheux et al. (35) 2013 30 pCR 53 Second >62% 86 63 N/A
SUV ≤ 3.0§ 86 94 88
Humbert et al. (34) 2014 54 pCR 41 First >60% 83 52 84
SUV < 2.1§ 59 88 76
*

pCR = pathologic complete response, defined as absence of residual invasive tumor in breast, irrespective of lymph node status [ypT0/is ypNX], unless otherwise indicated; pMRD = minimal residual disease, defined as a few scattered foci of microscopic residual invasive tumor (≤2 mm); pCR-macro = pathologic response, defined as absence of macroscopically visible tumor.

pCR was defined as absence of residual invasive tumor in both breast and axillary lymph nodes [ypT0/is ypN0].

Results were based on HER2-positive breast cancers only.

§

Absolute SUVs for defining cutoff values.

N/A = not available.